Literature DB >> 22011954

Multiple sclerosis and pregnancy.

Alex Tsui1, Martin A Lee.   

Abstract

PURPOSE OF REVIEW: Multiple sclerosis (MS) is a chronic inflammatory neurological condition typically affecting women of childbearing age. This review addresses questions that often arise in this patient group during pregnancy including the effects of pregnancy on relapse rates and long-term disease course, up-to-date advice on the use of disease-modifying MS treatments during pregnancy, the management of relapses in pregnancy and postpartum and current advice on breast feeding. RECENT
FINDINGS: Pregnancy is associated with a reduction in relapse frequency most marked in the final trimester with a comparable increase in relapse risk in the first 3 months postpartum. Studies examining exposure to MS therapies glatiramer acetate and interferon-beta during pregnancy have produced few negative outcomes offering the possibility of offering treatment until conception. Although initial data suggested breast feeding reduced MS relapses, the latest study demonstrated no significant benefit.
SUMMARY: Pregnancy is safe in most MS patients and does not negatively influence MS disease course overall. Use of disease-modifying treatments around conception should be considered on a case-by-case basis, weighing risks of drug exposure against risks of relapses. Whether breast feeding produces beneficial effects on MS relapses remain inconclusive.

Entities:  

Mesh:

Year:  2011        PMID: 22011954     DOI: 10.1097/GCO.0b013e32834cef8f

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  5 in total

Review 1.  Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis.

Authors:  Dionne P Robinson; Sabra L Klein
Journal:  Horm Behav       Date:  2012-03-03       Impact factor: 3.587

Review 2.  Multiple sclerosis and pregnancy; What a neurologist may be asked for?

Authors:  Bahaadin Siroos; Mohammad Hossein Harirchian
Journal:  Iran J Neurol       Date:  2014-04-03

3.  Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.

Authors:  Susan Friend; Sandra Richman; Gary Bloomgren; Lynda M Cristiano; Madé Wenten
Journal:  BMC Neurol       Date:  2016-08-24       Impact factor: 2.474

Review 4.  Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.

Authors:  Raed Alroughani; Ayse Altintas; Mohammed Al Jumah; Mohammadali Sahraian; Issa Alsharoqi; Abdurahman AlTahan; Abdulkader Daif; Maurice Dahdaleh; Dirk Deleu; Oscar Fernandez; Nikolaos Grigoriadis; Jihad Inshasi; Rana Karabudak; Karim Taha; Natalia Totolyan; Bassem I Yamout; Magd Zakaria; Saeed Bohlega
Journal:  Mult Scler Int       Date:  2016-12-18

5.  Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy Are Indicative of a Shift from Immune Tolerance to Immune Activation.

Authors:  Nishel Mohan Shah; Anna A Herasimtschuk; Adriano Boasso; Adel Benlahrech; Dietmar Fuchs; Nesrina Imami; Mark R Johnson
Journal:  Front Immunol       Date:  2017-09-15       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.